These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34267356)

  • 41. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mineralocorticoid receptor activation and oxidative stress.
    Funder JW
    Hypertension; 2007 Nov; 50(5):840-1. PubMed ID: 17923584
    [No Abstract]   [Full Text] [Related]  

  • 43. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials.
    Ng KP; Arnold J; Sharif A; Gill P; Townend JN; Ferro CJ
    J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):599-613. PubMed ID: 25784710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reconsidering the roles of the mineralocorticoid receptor.
    Funder JW
    Hypertension; 2009 Feb; 53(2):286-90. PubMed ID: 19139379
    [No Abstract]   [Full Text] [Related]  

  • 45. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
    Shavit L; Lifschitz MD; Epstein M
    Kidney Int; 2012 May; 81(10):955-968. PubMed ID: 22336987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineralocorticoid receptor blockers and chronic kidney disease.
    Jain G; Campbell RC; Warnock DG
    Clin J Am Soc Nephrol; 2009 Oct; 4(10):1685-91. PubMed ID: 19729430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers.
    Nishiyama A; Hitomi H; Rahman A; Kiyomoto H
    J Pharmacol Sci; 2009 Jan; 109(1):1-6. PubMed ID: 19151533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure.
    Soomro QH; Charytan DM
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):843-845. PubMed ID: 34117077
    [No Abstract]   [Full Text] [Related]  

  • 51. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence.
    Stolfo D; Savarese G
    Eur J Heart Fail; 2020 May; 22(5):845-847. PubMed ID: 32103601
    [No Abstract]   [Full Text] [Related]  

  • 53. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mineralocorticoid Receptor and Cardiovascular Disease.
    Buonafine M; Bonnard B; Jaisser F
    Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
    Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
    Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The aldosterone receptor--new insights?
    Fuller P
    Expert Opin Investig Drugs; 2006 Mar; 15(3):201-3. PubMed ID: 16503757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism.
    Sica DA; Gehr TW; Yancy C
    Congest Heart Fail; 2003; 9(4):224-9. PubMed ID: 12937359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment for symptoms of pseudoaldosteronism].
    Shibata H; Ito H
    Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):805-10. PubMed ID: 17506322
    [No Abstract]   [Full Text] [Related]  

  • 60. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
    Chrissobolis S
    Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.